Efficacy and Safety of Thai Herbal Formularies Benja Amarit in Hepatocellular Carcinoma Patients: Clinical Trial Phase II
- Conditions
- This study to explore effficacy and safty of Thai herbal formularies Benja Amarit in hapatocellular carcinoma (Clinical trail phase II). Study in hepatocellular carcinoma patient,Child-Pugh score AHepatocellular carcinoma,Thai Herbal Formularies Benja Amarit,Thai herbal
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 81
1. Patients who have been diagnosed is Hepatocellular carcinoma Child-Pugh score class A OR B.
2. Patients who cannot treat by standard treatment.
3. Stop another treatment not less than 4 weeks.
4. Stop radiation and chemotherapy not less than 4 weeks.
5. Thai, age between 18-80 years.
6. Zubrod-ECOG-WHO score between 0-2.
7. Patients who was evaluated to survival more than 5 months.
8.
- To understand Thai language and to communicate with research assistants to assess side effects from treatment
- Can receive medication and follow up as prescribed
- Consent and sign the name in research
1. Patients who have been allergy to ingredient of formularies Benja Amarit
2. Pregnant or breastfeeding women.
3. Receive chemotherapy or use herb or vitamin, its out of standard treatment.
4. Patient who have acute illness such as sepsis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival day 0 28 56 84 112 140 Duration of survival
- Secondary Outcome Measures
Name Time Method RECIST Criteria day 28 112 state of RECIST Criteria,Quality of life day 0 28 56 84 112 140 Thai Modified Function Living Index Cancer Questionnaire Version 2,safety day 0 28 56 84 112 140 Number of adverse drug event